Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06754228 · ClinicalTrials.gov registry record · NA

Acute Immune Modulation by Probiotic Strain

A NA study of Immune Surveillance, sponsored by Natural Immune Systems.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT06754228: Recruiting NA study of Immune Surveillance, sponsored by Natural Immune Systems.

NCT06754228 is a NA study of Immune Surveillance that is actively recruiting participants, run by Natural Immune Systems. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06754228, a NA study of Immune Surveillance, is actively recruiting participants, sponsored by Natural Immune Systems.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Clinical proof-of-concept study, comparing the acute immune impacts of 3 doses of a probiotic strain to a placebo. This study involves twenty-four participants, composed of healthy adults, who will be taking a placebo and 3 different doses of the probiotic at different times. Testing for immune status and cytokine levels will be conducted to determine the acute impact of the probiotic on immune function when compared to a placebo.

Primary Outcome

Changes in serum cytokine levels

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Probiotic Agent

Study Locations (1)

Oregon

  • NIS Labs - Klamath Falls

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-11-13
Est. Completion 2025-12-15
Phase NA
Natural Immune Systems

17 total trials

What NCT06754228 shows while recruiting

NCT06754228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Immune Surveillance appearing as the primary indexed condition, and to 1 intervention - of which Probiotic Agent is the first listed.

NCT06754228 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT06754228 about?

NCT06754228 is a clinical study titled "Acute Immune Modulation by Probiotic Strain". Clinical proof-of-concept study, comparing the acute immune impacts of 3 doses of a probiotic strain to a placebo. This study involves twenty-four participants, composed of healthy adults, who will be taking a placebo and 3 different doses of the probiotic at different times. Testing for immune stat...

What is the current status of trial NCT06754228?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2024-11-13. Estimated completion is 2025-12-15.

What conditions does trial NCT06754228 study?

This clinical trial studies the following conditions: Immune Surveillance.

What interventions are being tested in trial NCT06754228?

The interventions under investigation include: Probiotic Agent (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06754228?

This trial is sponsored by Natural Immune Systems, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06754228 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Immune Surveillance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06754228's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06754228, the US trial registry maintained by the National Library of Medicine. NCT06754228 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.